Targets › AKT2
7 programs from 6 companies in 51 trials: 22 Phase 2, 17 Phase 1, 12 Phase 3; Oncology, Other, Gastroenterology; next expected readout Nov 2026.
Serine/threonine kinase closely related to AKT1 and AKT3. All 3 enzymes, AKT1, AKT2 and AKT3, are collectively known as AKT kinase. (UniProt, P31751)
Open in Phaseline: the race on AKT2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AstraZeneca | Capivasertib Serine/threonine-protein kinase AKT inhibitor | AKT2, AKT3, AKT1 | Phase 3 | Locally Advanced (Inoperable) or Metastatic Breast Cancer; Prostate Cancer; Triple Negative Breast Neoplasms; Breast Cancer … | Nov 2026 |
| Laekna | Afuresertib Serine/threonine-protein kinase AKT inhibitor | AKT2, AKT3, AKT1 | Phase 3 | Breast Cancer | Dec 2026 |
| Roche | Ipatasertib Serine/threonine-protein kinase AKT inhibitor | AKT2, AKT3, AKT1 | Phase 3 | Cancer; Ovarian Cancer; Solid Tumors; Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer … | Feb 2028 |
| National Cancer Institute (NCI) | Uprosertib Serine/threonine-protein kinase AKT inhibitor | AKT2, AKT3, AKT1 | Phase 2 | Recurrent Uveal Melanoma | Jul 2027 |
| Merck & Co. (MSD) | Miransertib (MK-7075) Serine/threonine-protein kinase AKT inhibitor | AKT2, AKT3, AKT1 | Phase 2 | PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS); Proteus Syndrome | Feb 2030 |
| QuantumLeap Healthcare Collaborative | MK-2206 Serine/threonine-protein kinase AKT inhibitor | AKT2, AKT3, AKT1 | Phase 2 | Breast Neoplasms | Dec 2030 |
| National Cancer Institute (NCI) | Mk-2206 (MK2206) Serine/threonine-protein kinase AKT inhibitor | AKT2, AKT3, AKT1 | Phase 1 | Advanced Malignant Solid Neoplasm | Mar 2027 |
Breast Cancer (5) Metastatic Breast Cancer (4) Advanced Lymphoma (3) Locally Advanced (Inoperable) or Metastatic Breast Cancer (2) Prostate Cancer (2) Triple Negative Breast Neoplasms (2) Hormone-Sensitive Prostate Cancer (1) Locally Advanced or Metastatic Breast Cancer (1) Moderate Hepatic Impairment (1) Metastatic Castration-resistant Prostate Cancer (mCRPC) (1) CCCA Assessed by Ki67 Drop Below <2.7% From Baseline (1) Premenopausal Breast Cancer (1)
mixed (4), small molecule (3)
National Cancer Institute (NCI) (2) AstraZeneca (1) Merck & Co. (MSD) (1) Roche (1) Laekna (1) QuantumLeap Healthcare Collaborative (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.